Immunome
IMNM
24 hedge funds and large institutions have $10.1M invested in Immunome in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
37% more capital invested
Capital invested by funds: $7.35M → $10.1M (+$2.75M)
0.11% less ownership
Funds ownership: 19.84% → 19.73% (-0.11%)
8% less funds holding
Funds holding: 26 → 24 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$65.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8K |
| 3 |
BlackRock
New York
|
+$10.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$10.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$7.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$61.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.5K |
| 3 |
TC
Titleist Capital
San Antonio,
Texas
|
-$32K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
| 5 |
Morgan Stanley
New York
|
-$3.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$56.5K | -12,052 | Closed |
|
|
TC
27
Titleist Capital
San Antonio,
Texas
| – | -$32K | -10,000 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$8K | -2,489 | Closed |
|
IMNM Hedge Fund Activity: Q3 2022 in Review
24 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2022, worth a combined $10.1M — up 37% from $7.35M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IMNM and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was UBS Group, adding an estimated $65.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $61.7K sold.
- 24 institutional investors held Immunome (IMNM) as of Q3 2022, down from 26 in Q2 2022.
- Funds reported $10.1M of Immunome stock for Q3 2022, up 37% quarter-over-quarter.
- 2 funds opened new Immunome positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest Immunome buyer in Q3 2022 was UBS Group, an estimated $65.4K added.
- The largest Immunome seller in Q3 2022 was Citadel Advisors, an estimated $61.7K sold.
Based on aggregated 13F filings for Q3 2022.